Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

ClinicalTrials.gov ID: NCT00439777

Public ClinicalTrials.gov record NCT00439777. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic Deep-Vein Thrombosis (DVT) (Einstein-PE).

Study identification

NCT ID: NCT00439777
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 4,833 participants

Conditions and interventions

Conditions

Pulmonary Embolism

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2007 (Type not available)
Primary completion: Sep 2011 (Actual)
Completion: Dec 2011 (Actual)
Last update posted: Feb 27, 2014

2007 – 2011

United States locations

U.S. sites: 23
U.S. states: 16
U.S. cities: 21

Facility	City	State	ZIP	Site status
Not listed	Little Rock	Arkansas	72205	—
Not listed	Redlands	California	92373	—
Not listed	Bay Pines	Florida	33744	—
Not listed	Miami	Florida	33136-1096	—
Not listed	Miami	Florida	33136	—
Not listed	Idaho Falls	Idaho	83404	—
Not listed	Covington	Louisiana	70433	—
Not listed	Baltimore	Maryland	21215	—
Not listed	Boston	Massachusetts	02215	—
Not listed	Chesterfield	Missouri	63017	—
Not listed	Albuquerque	New Mexico	87108	—
Not listed	Chapel Hill	North Carolina	27599-7035	—
Not listed	Greensboro	North Carolina	27401	—
Not listed	Greensboro	North Carolina	27403	—
Not listed	Oklahoma City	Oklahoma	73104	—
Not listed	Camp Hill	Pennsylvania	17011	—
Not listed	Pittsburgh	Pennsylvania	15224	—
Not listed	San Antonio	Texas	78229	—
Not listed	Murray	Utah	84107	—
Not listed	Salt Lake City	Utah	84132	—
Not listed	Fredericksburg	Virginia	22401	—
Not listed	Spokane	Washington	99204	—
Not listed	Tacoma	Washington	98405	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 282 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00439777, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 27, 2014 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00439777 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →